Ireland
--:--IST
Latest
Clinical Trials in Switzerland / NCT06936774
Recruiting Phase 3

Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance

NCT06936774 · tracked via the Priya Life Science Switzerland tracker
Phase
Phase 3
Started
2025-12-01
Last updated
2026-05-06

Condition(s) studied

LARS - Low Anterior Resection SyndromeRectal Cancer SurgeryRectal CancerQuality of Life (QOL)

Investigational drug(s) / intervention(s)

Intensified follow-up program

Intensified follow-up program: The study intervention will be an intensified follow-up program which consists of different measures. Patients will attend follow-up visits 1, 4, 7 and 13 months after ileostomy repositioning, at which LARS symptoms, quality of life as well as sexual and urinary function will be recorded using various questionnaires. In case of LARS symptoms patients will receive medical treatment with loperamide and metamucil as well as pelvic floor muscle training (including biofeedback and home exercises). Regarding pelvic floor muscle training we are planning nine sessions instructed by physiotherapy staff. In case of therapy-resistant LARS symptoms after 6 months sacral neurostimulation is offered to the patients with a focus on incontinence symptoms and desire for surgery or transanal irrigation in patients with a focus on voiding disorders. In case of urinary and sexual complaints patients are referred to our urology or gynaecology department for further diagnostic and treatment.

Study summary

The goal of this clinical study is to gain further insights into the treatment of patients with Low Anterior Resection Syndrome (LARS) symptoms after rectal resection. The main question is: Can LARS symptoms and quality of life be improved by implementing an intensified follow-up program? Researchers will compare the results of the intervention group with the results of a control group in which patients do not receive an intensified follow-up program to determine whether the intervention works. Participants will undergo an intensified follow-up program which consists of several follow-up visits and medical treatment, pelvic floor muscle training and gynaecological and urological co-treatment in case of LARS symptoms and urinary or sexual complaints.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients older than 18 years * patients with rectal cancer in the middle and lower third of the rectum in stages I to IV who underwent LAR with TME and protective ileostomy * able to give informed consent as documented by signature Exclusion Criteria: * dementia or other psychiatric disorder that would prevent the patients from answering the questionnaires and experiencing sustainable training effects * impossibility of stoma reversal due to persistent anastomotic leak and/or local recurrence

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Clarunis Universitäres Bauchzentrum Basel Basel Switzerland Recruiting
Lindenhofspital Bern Bern Switzerland Recruiting
St. Anna Spital Bern Bern Switzerland Not Yet Recruiting
Kantonsspital Luzern Lucerne Switzerland Recruiting
Kantonsspital Winterthur Winterthur Switzerland Recruiting

More University Hospital, Basel, Switzerland trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06936774 on ClinicalTrials.gov ↗ ← All trials in Switzerland